Meningococcal Meningitis by Flægstad, Trond
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books









Meningococcal disease may present as meningitis, septicemia, or a combination of 
the two. Generally, meningitis has a gradual onset, with fever, headache, and neck 
stiffness as the most frequent clinical symptoms. By contrast, fulminant septicemia 
may develop within hours, and is characterized by petechial bleedings and shock. 
It is of vital importance to diagnose and treat meningococcal disease rapidly. The 
diagnosis is based on the culture of Neisseria meningitides from blood or cerebrospinal 
fluid, or on the polymerase chain reaction (PCR) of spinal fluid. Cefotaxime or 
ceftriaxone are usually recommended as antibacterial treatment. There is a vaccine 
effective against disease with serogroups A, C, Y, and W.
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1. Clinical features of meningococcal disease
Meningococcal disease is one of the most devastating infections in an individual 
or community, and is caused by the bacterium Neisseria meningitidis with diseases 
most often in the forms of meningitis, septicemia, or a combination of meningitis 
and septicemia [1–4]. The onset can be nonspecific, but is usually abrupt with 
symptoms as fever, malaise, and myalgia, and a rash that initially may be urticarial, 
maculopapular, or petechial (purpuric). Fulminant meningococcal septicemia is 
usually characterized by the rapid development of hypotension, ecchymosis, and 
disseminated intravascular coagulation (DIC).
Meningitis is characterized by gradual onset of fever, headache, neck-stiffness, 
backache, and nausea.
In meningococcal meningitis, drowsiness, reduced cognitive function, stiff 
neck, and positive Kernig and Brudzinski’s signs, all manifestations of meningeal 
inflammation, are usually present along with fever. Neurological findings may be 
cranial nerve dysfunction, seizures, focal cerebral signs, and reduced conscious-
ness. The symptoms and signs of meningococcal meningitis are indistinguishable 
from those associated with acute meningitis caused by Haemophilus influenzae type 
b bacteria, Streptococcus pneumoniae, and other bacteria. However, the presence of 
petechiae strongly implicates N. meningitidis.
2. Typing systems and classification of Neisseria meningitidis
N. meningitidis is a Gram-negative diplococcus. Several methods for typing and 
classification of N. meningitidis exist. The system currently used most widely is based 
on antigenic differences of different bacterial surface structures and on susceptibil-
ity to sulfonamides. According to this scheme, meningococci are classified by:  
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(a) serogroup (capsular polysaccharides) (A, B, C, X, Y, W are most common in 
invasive disease); (b) serotype (the class 2 or 3 outer-membrane proteins); and (c) 
subtype (the class 1 outer-membrane protein). The phenotype of a meningococcus is 
written: serogroup:serotype:subtype. According to this, the epidemic strain in North 
Norway (serogroup B, serotype 15, subtype P1.7.16) is designated: B:15:P1.7.16 [5].
3. Epidemiology of meningococcal meningitis
N. meningitidis only infects humans; there is no animal reservoir. The bacteria 
can be carried in the throat and sometimes, for reasons not fully understood, can 
overwhelm the body’s defenses allowing infection to spread through the bloodstream 
to the brain. It is believed that 1–10% of the population carries N. meningitidis in 
their throat at any given time. However, the carriage rate may be higher in epidemic 
situations [6].
The bacteria are transmitted from person to person through droplets of respi-
ratory or throat secretions from carriers. Close and prolonged contact—such as 
kissing, sneezing or coughing on someone, or living in close quarters (such as a 
dormitory, sharing eating or drinking utensils) with an infected person facilitates 
the spread of the disease. The average incubation period is 4 days, but can range 
between 2 and 10 days.
Meningococcal disease occurs in almost every country in the world regardless of cli-
mate and economic development. Serogroup A disease has been most often associated 
with widespread epidemics in Africa where epidemics of serogroup A meningococcal 
disease tends to occur every 7–10 years in sub-Saharan Africa (Figure 1).
Figure 1. 




The highest rate of meningococcal disease occurs in children below 4 years of 
age, but all age groups may be affected [5–7].
The overall mortality rate for invasive meningococcal disease is 10–15%, while 
about 15% of the survivors suffer from permanent sequelae like hearing impair-
ment, neurological disability, and digit or limb amputation [3].
In 2015, there were 379,000 deaths caused by meningitis worldwide, of those 
73,000 by N. meningitis; most of these deaths were in children less than 5 years of 
age [6, 8].
4. Laboratory diagnosis of meningococcal meningitis
Initially, the diagnosis of meningococcal disease rests on clinical signs and 
symptoms. On admission, appropriate specimens should be immediately collected 
to ensure correct diagnosis.
4.1 Collection of appropriate specimens for bacteriological analysis
Antibacterial treatment of suspected meningococcal meningitis must be started 
as soon as possible and is often initiated before admission. To ensure correct diagno-
sis, it is important to collect bacteriological specimens before therapy is started. At 
the hospital, blood culture should always be collected. Cerebrospinal fluid (CSF) is 
collected for microscopy, culture, and detection of meningococci by antigen testing or 
by polymerase chain reaction (PCR). One drop of CSF is collected on microscope slide 
and dried in air for microscopy. One or two drops of CSF are tapped on a swab and 
placed in a tube of Amies or Stuart transport medium for culture. When placed in a 
transport medium, the bacteria will stay alive for a longer period of time than in liquid.
CSF can also be collected in a liquid culture medium, like a blood culture 
medium. Some laboratories supply clinical departments with agar culture media 
so that CSF can be collected directly on them before being sent to the laboratory. 
Finally, 1 ml of liquid CSF is collected in a sterile container for bacterial culture and 
polymerase chain reaction (PCR).
Because meningococci survive longer in the throat than in the CSF and blood 
after antibacterial treatment has started, a throat sample is highly recommended. 
The specimens should be sent to the laboratory and processed immediately. If the 
specimens have to be stored before transport, they should preferably be kept at 
8–10°C or at room temperature. Petechial skin lesions also represent a potential 
diagnostic specimen. Meningococci are often present in the petechiae, and Gram-
stain smears and culture of needle aspirates or punch biopsies from skin lesions are 
positive in up to 60% of cases [9]. This can be particularly useful when antibiotic 
treatment was started before cultures were obtained.
PCR can detect small quantities of bacterial DNA and is useful, because of 
results may be obtained after a few hours, and sensitivity is not affected by previous 
antibiotic treatment [10].
4.2 Microbiological diagnosis of meningococcal meningitis
4.2.1 Culture
Conventionally, culture is the standard method for making a diagnosis of 
meningococcal disease. If the specimens have to be stored before transport, they 
should preferably be kept at 4°C for CSF in order to be analyzed by PCR or at room 
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temperature (suitable for the strains in Amies medium, or cultures on chocolate 
agar medium) in order to be analyzed.
In the microbiology laboratory, CSF from patients with suspected meningococ-
cal meningitis is cultured on blood agar and chocolate agar overnight at 36.5–37.0°C 
in 10% CO2. In some laboratories, CSF is also cultured in blood-culture bottles or 
in another liquid medium. Throat specimens are cultured on agar media selecting 
growth of meningococci. Blood is cultured in commercially available bottles con-
taining a rich culture medium supporting the growth of a wide range of bacteria.
4.2.2 Microscopy and agglutination methods
A Gram-stained preparat of CSF is most often analyzed. Meningococci typically 
are seen as Gram-negative [red] coffee bean-like diplococci. A fluorescent staining 
method using acridine-orange which stains bacteria orange-red and human cells 
pale yellow has also proved valuable. Agglutination method, directly from sediment 
coming from CSF, after centrifugation, can be used to determine meningococcal 
serogroup, except for serogroup B.
4.2.3 Genetic methods
Microbial nucleic acids are stable and can be detected in body fluids and tissues 
even though the microbes are dead and are in very small quantities. Real-time PCR 
can give results in approximately 2 h, much easier by comparing with conventional 
PCR, and can give species and serogroup identification.
4.3 Nonbacterial tests
In meningococcal meningitis, the number of leukocytes and levels of acute 
phase proteins such as procalcitonin and C-reactive protein in the blood are nor-
mally elevated. The number of leukocytes in CSF usually exceeds 800 cells/mm3, 
and there is a relative increase in the number of granulocytes. The concentration of 
protein is increased and that of sugar decreased. In early stages of meningococcal 
meningitis, leukocytes may be absent from the CSF, although the culture later may 
grow meningococci. The absence of leucocytes does therefore not exclude bacterial 
meningitis.
5. Treatment of meningococcal meningitis
5.1 General principles
National and international guidelines for treatment of meningococcal disease 
exist, and our recommendations are based generally on these guidelines [3, 11]. 
In addition to prompt use of antimicrobial agents, the immediate treatment of 
increased intracranial pressure, seizures, and shock if present, must be started, 
and normal hydration and electrolyte balance must be restored. Because shock is 
a very early event and can often be life threatening, its management should take 
precedence over fluid restrictions aimed at preventing the inappropriate secretion 
of antidiuretic hormone. Infants with vomiting may show relative hypovolemia.
There is no report supporting the use of prophylactic glucocorticoid therapy in 
meningococcal meningitis. The majority of patients enrolled in trials with adjunc-
tive dexamethasone therapy are children with H. influenzae meningitis. The benefits 
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of glucocorticoid therapy may not extend to children with other pathogens, and the 
benefit in adults is even less clear.
5.2 Principles of antimicrobial treatment
Bacterial meningitis is an infection in an area of impaired host resistance. 
Specific antibodies and complement are frequently absent from the cerebrospinal 
fluid in patients with meningococcal meningitis, resulting in inefficient phagocy-
tosis and subsequent rapid bacterial multiplication. It is therefore necessary to treat 
meningitis with antimicrobial agents that are bactericidal, penetrate to the CSF 
easily, and rapidly reach bactericidal concentrations. The increased permeability 
of the blood-brain barrier during meningeal infection enhances the penetration of 
most antibiotics into CSF.
In experimental meningitis, it has been found that maximal bactericidal activ-
ity of an antibacterial agent occurs at a concentration 10–30 times greater than the 
minimal in vitro bactericidal concentration. Cranial imaging is required before 
spinal puncture in patients who are in coma, have papilledema, or have focal neu-
rological symptoms. Before imaging, adequate clinical specimens must be collected 
and empirical therapy started. Empirical therapy must be selected on the basis of 
the age of the patient, symptoms, and the local frequency of etiological bacterial 
pathogens.
In cases of suspected bacterial meningitis (or meningococcal sepsis), patients 
should be treated empirically to cover the most likely pathogens while awaiting 
culture results. Cefotaxime or ceftriaxone is usually recommended [3]. This might 
be changed to penicillin G when the diagnosis is bacteriologically confirmed. For 
patients with a life-threatening penicillin allergy characterized by anaphylaxis, 
chloramphenicol is recommended.
The duration of therapy is normally 7 days. Rare isolates of beta-lactamase 
producing meningococcal strains with high-level resistance have been described, as 
have clinical isolates with altered penicillin-binding proteins and intermediate resis-
tance to penicillin [MIC, 0.1–1.0 g/l]. Since many of these patients were successfully 
treated with benzylpenicillin, the importance of in vitro penicillin insensitivity in 
meningococci is unclear.
6. Prevention of meningococcal meningitis
6.1 Primary prevention of meningococcal disease
Vaccines against meningococcal disease exist, but protection is only against 
meningococcal disease of the same capsular polysaccharide present in the vaccine. 
A present, there are vaccines against serogroups A, C, Y, and W; commonly com-
bined in a quadrivalent conjugated vaccine (A, C, Y, W).
Recommended immunization with this vaccine is for children and adults with 
complement deficiency, asplenia, who are at risk during a community outbreak 
attributable to a vaccine serogroup, are residents or will travel to endemic areas, or 
are HIV positive [3]. The conjugate vaccines confer long-lasting immunity (5 years 
or more), prevent carriage, and induce herd immunity.
Polysaccharide vaccines are used during a response to outbreaks, mainly in Africa. 
They are either bivalent (A, C); trivalent (A, C, W); or tetravalent (A, C, Y, W) [6]. 
They are not effective before 2 years of age, offer a 3-year protection but do not induce 
herd immunity.
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At present, there is no long-lasting protective vaccine against the serogroup B 
meningococcus, but it is used in outbreak response [6].
6.2 Secondary prevention of meningococcal disease
Following a case of meningococcal disease, contacts should be vaccinated if 
the causative strain belongs to a serogroup against which a protective vaccine 
exists (A, C, Y, and W). However, it takes 2–3 weeks to produce protective anti-
bodies, during which period secondary disease may develop. The use of chemo-
prophylaxis to eradicate the disease-causing strain from close contact, thereby 
stopping the spread of the infection, is therefore recommended. Household 
members of a patient with meningococcal disease have a much higher risk of 
contracting the disease than the general population. Household members of the 
patient and kissing contacts are most likely to carry the disease-causing strain and 
need chemoprophylaxis. Other close contacts to whom chemoprophylaxis may be 
considered are babysitters including grandparents or other family members, and 
kindergarten employees. Rifampicin, ceftriaxone, or ciprofloxacin are the recom-
mended drugs [3].
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